Complete Filing Data
GOLDENWELL BIOTECH, INC. reported Net Income Loss of -$131.5 thousand for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean GOLDENWELL BIOTECH, INC. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income * | -$131.5K | -$117.4K | -$985.1K | -$117.0K | -$6.3K | -$2.3K |
| Revenue * | $139.00 | $2.3K | $47.8K | $16.0K | $0.00 | $0.00 |
| Operating Expenses | $123.2K | $116.5K | $1.0M | -$126.7K | $6.4K | $2.6K |
| Gross Profit | $64.00 | $666.00 | $25.2K | $8.4K | $0.00 | $0.00 |
| Cost Of Revenue | $75.00 | $1.2K | $22.6K | $7.6K | $0.00 | $0.00 |
| General And Administrative Expense | $123.2K | $116.5K | $1.0M | $126.7K | ||
| Operating Income Loss | -$123.1K | -$115.8K | -$985.1K | -$118.3K | ||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Other Nonoperating Income Expense | $8.00 | $1.3K | $44.00 | $0.00 | ||
| Interest Expense | $8.4K | $1.5K | $0.00 | $0.00 | $0.00 | |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$118.3K | -$6.4K | -$2.6K | |||
| Deferred Revenue | $1.9K | $1.4K | ||||
| Selling General And Administrative Expense | $126.7K | $6.4K | $2.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$8.0K | -$5.2K | -$34.4K | $23.1K | $49.9K | $31.0K | -$20.8K | -$35.4K | -$27.1K | -$33.6K | -$920.3K | -$4.6K | -$26.8K | -$33.4K | -$29.5K | -$87.4K | -$23.6K | -$46.1K | -$3.0K | -$879.00 | -$141.00 | -$2.3K | -$2.3K | -$2.0K | |
| Revenue * | $0.00 | $0.00 | $0.00 | $139.00 | $158.00 | $260.00 | $382.00 | $276.00 | $1.4K | $0.00 | $43.7K | $3.7K | $397.00 | $12.2K | $1.1K | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Operating Expenses | $30.9K | $40.6K | $32.3K | $21.0K | $47.9K | $29.0K | $20.9K | $35.6K | $27.2K | -$34.3K | $920.3K | $27.6K | $28.8K | $33.6K | $95.1K | -$24.4K | -$46.9K | $884.00 | -$146.00 | $2.4K | $2.0K | ||||
| Gross Profit | $25.0K | $37.5K | $0.00 | $0.00 | $70.00 | $0.00 | $73.00 | $186.00 | $138.00 | $711.00 | $0.00 | $23.0K | $2.0K | $209.00 | $6.4K | $581.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Cost Of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $69.00 | $0.00 | $187.00 | $196.00 | $138.00 | $711.00 | $0.00 | $20.7K | $1.8K | $188.00 | $5.8K | $525.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| General And Administrative Expense | $30.9K | $40.6K | $32.3K | $21.0K | $47.9K | $29.0K | $20.9K | $35.6K | $27.2K | $34.3K | $920.3K | $27.6K | $28.8K | $33.6K | $95.1K | $24.4K | |||||||||
| Operating Income Loss | -$5.9K | -$3.1K | -$32.3K | -$21.0K | -$47.8K | -$29.0K | -$20.8K | -$35.4K | -$27.1K | -$33.6K | -$920.3K | -$4.6K | -$26.8K | -$33.4K | -$88.7K | ||||||||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||
| Other Nonoperating Income Expense | $0.00 | $0.00 | $0.00 | $1.00 | $7.00 | $1.3K | $264.00 | $750.00 | $5.00 | $29.00 | $12.00 | ||||||||||||||
| Interest Expense | $2.1K | $2.1K | $2.1K | $2.1K | $2.1K | $2.1K | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$26.8K | -$33.4K | -$18.0K | -$23.8K | -$46.9K | -$884.00 | -$146.00 | -$2.4K | -$2.0K | ||||||||||||||||
| Deferred Revenue | $1.9K | $1.9K | $1.9K | $1.9K | $1.2K | $1.2K | $1.2K | $1.4K | $1.4K | $1.4K | |||||||||||||||
| Selling General And Administrative Expense | $33.6K | $23.8K | $24.4K | $46.9K | $884.00 | $146.00 | $2.4K | $2.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $201.6K | $301.7K | $248.6K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $46.0K | $213.6K | $248.6K | ||||
| Retained Earnings Accumulated Deficit | -$1.2M | -$1.1M | -$125.7K | -$8.6K | -$2.3K | ||
| Liabilities And Stockholders Equity | $228.1K | $248.4K | $461.0K | $248.6K | $246.6K | ||
| Liabilities | $143.8K | $46.8K | $159.3K | $0.00 | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$3.8K | $7.2K | -$167.6K | -$35.0K | |||
| Assets | $228.1K | $248.4K | $461.0K | $248.6K | $246.6K | ||
| Common Stock Value | $9.9K | $9.9K | $9.6K | $9.2K | $8.0K | ||
| Inventory Net | $174.9K | $176.1K | $198.7K | $0.00 | |||
| Cash And Cash Equivalents At Carrying Value | $46.0K | $213.6K | $246.6K | $0.00 | |||
| Operating Lease Right Of Use Asset | $26.3K | $48.8K | $0.00 | ||||
| Operating Lease Liability Current | $25.4K | $47.8K | $0.00 | ||||
| Accounts Payable Current | $0.00 | $111.5K | $0.00 | ||||
| Liabilities Current | $0.00 | $0.00 | |||||
| Stock Subscription Receivable | $0.00 | $0.00 | $78.2K | -$78.3K | |||
| Other Liabilities | $20.0K | ||||||
| Cash | $46.0K | $213.6K | $246.6K | $0.00 | |||
| Amortization Of Debt Discount Premium | $0.00 | $0.00 | $0.00 | ||||
| Discount On Long Term Liabilities | -$23.7K | ||||||
| Cash And Cash Equivalents Period Increase Decrease | -$35.0K | $2.0K | $246.6K | ||||
| Accrued Liabilities And Other Liabilities | $0.00 | $0.00 | $0.00 | ||||
| Operating Lease Liability Noncurrent | $0.00 | $0.00 | |||||
| Common Stock Shares Subscriptions | 7.6K | ||||||
| Accounts Receivable Net | $0.00 | $0.00 | |||||
| Other Liabilities Noncurrent | $70.0K | ||||||
| Cash Receipt From Stock Subscription Receivable |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$94.8K | -$86.8K | -$81.6K | -$47.2K | $19.2K | $3.8K | $53.7K | $84.7K | $105.5K | $140.9K | $168.0K | $237.0K | $241.5K | $268.3K | $331.3K | $349.0K | $372.6K | $250.5K | $251.4K | $251.6K | $246.6K | $0.00 | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $45.6K | $76.5K | $17.1K | $49.4K | $4.8K | $25.7K | $24.2K | $53.2K | $11.9K | $17.1K | $44.1K | $58.1K | $42.9K | $213.6K | $232.9K | $245.4K | ||||||||
| Retained Earnings Accumulated Deficit | -$1.4M | -$1.4M | -$1.4M | -$1.4M | -$1.3M | -$1.3M | -$1.3M | -$1.2M | -$1.2M | -$1.1M | -$190.5K | -$185.9K | -$159.1K | -$96.2K | -$78.4K | -$54.8K | -$5.7K | |||||||
| Liabilities And Stockholders Equity | $220.4K | $251.3K | $191.9K | $224.2K | $179.4K | $200.4K | $199.0K | $186.9K | $192.3K | $219.4K | $266.1K | $274.4K | $308.7K | $485.8K | $509.2K | $435.2K | $250.5K | |||||||
| Liabilities | $315.2K | $338.1K | $273.5K | $271.4K | $198.7K | $196.6K | $145.2K | $81.4K | $51.4K | $51.4K | $29.1K | $32.9K | $40.4K | $154.6K | $160.2K | $62.6K | $0.00 | |||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $59.4K | -$32.3K | $1.5K | -$29.0K | -$5.2K | -$26.9K | -$1.9K | $15.2K | -$25.0K | -$145.7K | -$12.5K | $19.9K | $19.9K | |||||||||||
| Assets | $220.4K | $251.3K | $191.9K | $224.2K | $179.4K | $200.4K | $199.0K | $186.9K | $192.3K | $219.4K | $266.1K | $274.4K | $308.7K | $485.8K | $509.2K | $435.2K | $250.5K | |||||||
| Common Stock Value | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.9K | $9.6K | $9.6K | $9.6K | $9.6K | $9.6K | $9.6K | ||||||||
| Inventory Net | $174.8K | $174.8K | $174.8K | $174.8K | $174.7K | $174.7K | $174.7K | $175.0K | $175.2K | $175.3K | $176.1K | $196.7K | $198.5K | $200.5K | $205.7K | $103.1K | ||||||||
| Cash And Cash Equivalents At Carrying Value | $25.7K | $53.2K | $42.9K | $67.9K | $232.9K | $245.4K | $248.6K | $248.6K | $250.5K | $251.4K | $251.6K | $0.00 | ||||||||||||
| Operating Lease Right Of Use Asset | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $31.1K | $34.8K | $42.3K | $52.4K | $58.0K | $63.6K | ||||||||
| Operating Lease Liability Current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $29.1K | $32.9K | $40.4K | $22.9K | $22.8K | $17.1K | ||||||||||||
| Accounts Payable Current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $103.1K | $103.1K | ||||||||||
| Liabilities Current | $39.4K | $64.4K | $1.9K | $29.1K | $32.9K | $40.4K | $159.3K | $126.0K | $0.00 | $0.00 | $0.00 | |||||||||||||
| Stock Subscription Receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||||
| Other Liabilities | $214.8K | $214.8K | $165.6K | $165.6K | $80.0K | $50.0K | $50.0K | |||||||||||||||||
| Cash | $25.7K | $53.2K | $42.9K | $67.9K | $232.9K | $245.4K | $248.6K | $248.6K | $250.5K | $251.4K | $251.6K | $0.00 | ||||||||||||
| Amortization Of Debt Discount Premium | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||||||
| Discount On Long Term Liabilities | -$9.0K | -$11.1K | -$13.2K | -$15.3K | $17.4K | $19.5K | ||||||||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | $19.9K | $5.0K | ||||||||||||||||||||||
| Accrued Liabilities And Other Liabilities | $125.9K | $0.00 | $0.00 | |||||||||||||||||||||
| Operating Lease Liability Noncurrent | $28.6K | $34.2K | $45.5K | |||||||||||||||||||||
| Common Stock Shares Subscriptions | 0.00 | 78.3K | -300.00 | 208.9K | 209.2K | |||||||||||||||||||
| Accounts Receivable Net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||||
| Other Liabilities Noncurrent | $189.3K | $189.3K | $189.3K | $189.3K | ||||||||||||||||||||
| Cash Receipt From Stock Subscription Receivable | $7.3K | $78.3K | $1.0K | $7.3K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$123.1K | -$113.2K | -$1.1M | -$205.1K | -$6.3K | -$2.3K |
| Net Cash Provided By Used In Financing Activities | $119.3K | $120.4K | $905.0K | $170.1K | $8.3K | $248.9K |
| Increase Decrease In Inventories | -$75.00 | -$1.2K | $22.6K | $198.7K | $0.00 | |
| Increase Decrease In Operating Lease Liability | $0.00 | -$25.4K | -$22.4K | $47.8K | ||
| Proceeds From Issuance Of Common Stock | $0.00 | $300.00 | $91.9K | $8.3K | $248.9K | |
| Increase Decrease In Accounts Payable | -$111.5K | $111.5K | $0.00 | |||
| Proceeds From Issuance Of Long Term Debt | $119.3K | $70.0K | $20.0K | |||
| Increase Decrease In Accounts Receivable | $0.00 | $0.00 | $0.00 | |||
| Increase Decrease In Right Of Use Asset | $26.3K | $22.4K | $48.8K | |||
| Increase Decrease In Other Accrued Liabilities | $0.00 | $0.00 | $0.00 | |||
| Increase Decrease In Deferred Revenue | -$54.00 | $504.00 | $1.4K | |||
| Proceeds From Issuance Or Sale Of Equity | $78.2K | $0.00 | ||||
| Proceeds From Discount On Long Term Loan | ||||||
| Increase Decrease In Inventories Deposit | $0.00 | $0.00 | ||||
| Proceeds From Stock Subscription Receivable | ||||||
| Proceeds From Additional Paid Capital | ||||||
| Increase Decrease In Other Deferred Liability | $47.8K | $0.00 | ||||
| Increase Decrease In Change In Right Of Use Asset | ||||||
| Proceeds From Contributed Capital | $0.00 | $884.7K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | $59.4K | -$32.3K | -$47.8K | -$29.0K | -$35.2K | -$26.9K | -$31.9K | $15.2K | -$25.0K | -$145.7K | -$12.5K | -$150.2K | -$150.2K | -$2.3K |
| Net Cash Provided By Used In Financing Activities | $0.00 | $49.3K | $2.1K | $30.0K | $30.0K | $0.00 | $170.1K | $170.1K | $7.3K | |||||
| Increase Decrease In Inventories | -$69.00 | $79.00 | -$196.00 | -$138.00 | $711.00 | -$20.7K | -$1.8K | $0.00 | -$5.3K | $103.1K | $0.00 | |||
| Increase Decrease In Operating Lease Liability | $0.00 | $0.00 | $0.00 | -$25.4K | -$3.7K | -$7.5K | -$7.4K | -$5.6K | $62.6K | $62.6K | ||||
| Proceeds From Issuance Of Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $91.9K | $91.9K | $0.00 | |||||||
| Increase Decrease In Accounts Payable | $0.00 | $0.00 | $0.00 | $0.00 | -$111.5K | |||||||||
| Proceeds From Issuance Of Long Term Debt | $49.3K | $30.0K | $30.0K | |||||||||||
| Increase Decrease In Accounts Receivable | $0.00 | $0.00 | $0.00 | $0.00 | $857.00 | |||||||||
| Increase Decrease In Right Of Use Asset | $0.00 | $26.3K | -$3.7K | -$7.5K | $6.5K | |||||||||
| Increase Decrease In Other Accrued Liabilities | $0.00 | $0.00 | $0.00 | |||||||||||
| Increase Decrease In Deferred Revenue | $0.00 | -$54.00 | $0.00 | |||||||||||
| Proceeds From Issuance Or Sale Of Equity | $78.2K | $78.2K | $7.3K | |||||||||||
| Proceeds From Discount On Long Term Loan | $0.00 | $0.00 | ||||||||||||
| Increase Decrease In Inventories Deposit | $0.00 | $0.00 | $0.00 | |||||||||||
| Proceeds From Stock Subscription Receivable | $0.00 | $0.00 | ||||||||||||
| Proceeds From Additional Paid Capital | $0.00 | $0.00 | ||||||||||||
| Increase Decrease In Other Deferred Liability | $62.6K | $0.00 | ||||||||||||
| Increase Decrease In Change In Right Of Use Asset | $3.7K | $7.5K | $5.6K | -$63.6K | ||||||||||
| Proceeds From Contributed Capital | $0.00 | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Diluted EPS * | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Issued | 99.0M | 99.0M | 91.5M | 80.0M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |
| Common Stock Shares Outstanding | 99.0M | 99.0M | 91.5M | 91.5M | 80.0M | |
| Weighted Average Number Of Shares Outstanding Basic And Diluted | 96.4M | 96.4M | 91.3M | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 91.3M | 80.0M | 76.2M | |||
| Shares Issued For Cash001Stock Price Amount | 0.00 | |||||
| Shares Issued For Cash Stock Price Amount | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 99.0M | 99.0M | ||||
| Shares Issued For Cash Stock Price Shares | ||||||
| Shares Issued For Cash001And Stock Price Shares | ||||||
| Shares Issued For Cash0001Stock Price Amount | 0.00 | |||||
| Earning Per Share Basic And Diluted | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||
| Common Stock Shares Issued | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 96.0M | 96.0M | 96.0M | 96.0M | 96.0M | 96.0M | 2.4M | 80.0M | ||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 3.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | ||||||
| Common Stock Shares Outstanding | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 99.0M | 96.0M | 96.0M | 96.0M | 96.0M | 96.0M | 96.0M | 80.0M | |||||||
| Weighted Average Number Of Shares Outstanding Basic And Diluted | 96.4M | 96.4M | 96.4M | 96.4M | 96.4M | 96.4M | 96.4M | 96.4M | 91.3M | 91.3M | 91.3M | 91.3M | 91.3M | 80.0M | ||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 91.3M | 91.3M | 91.3M | 80.0M | 80.0M | 80.0M | 28.1M | |||||||||||||||||
| Shares Issued For Cash001Stock Price Amount | 0.00 | 0.00 | 0.00 | 10.0K | 0.00 | 0.00 | ||||||||||||||||||
| Shares Issued For Cash Stock Price Amount | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 96.4M | 96.4M | 99.0M | 96.4M | 96.4M | 99.0M | ||||||||||||||||||
| Shares Issued For Cash Stock Price Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||||||
| Shares Issued For Cash001And Stock Price Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||||||
| Shares Issued For Cash0001Stock Price Amount | 0.00 | 1.4K | 0.00 | 0.00 | ||||||||||||||||||||
| Earning Per Share Basic And Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Other Income | $8.00 | $1.3K | $44.00 | $290.00 | |
| Additional Paid In Capital | $1.3M | $1.3M | $417.8K | $326.4K | $248.5K |
| Stock Issued During Period Value New Issues | |||||
| Loan From Director | $0.00 | $0.00 | $0.00 | ||
| Gain Loss On Derivative Instruments Net Pretax | $0.00 | $0.00 | $0.00 | ||
| Due To Related Parties Current | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $7.00 | $1.3K | $264.00 | $750.00 | $5.00 | $5.00 | $29.00 | ||||||
| Additional Paid In Capital | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $417.8K | $417.8K | $417.8K | $417.8K | $417.8K | $417.8K | $248.5K | |||||
| Stock Issued During Period Value New Issues | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $500.00 | $215.3K | |||||||||||||||
| Loan From Director | $0.00 | $0.00 | $0.00 | |||||||||||||||||||
| Gain Loss On Derivative Instruments Net Pretax | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||||||||||
| Due To Related Parties Current | $0.00 | $0.00 | $0.00 |
Most recent annual filing with the SEC: May 15, 2025
Data sourced from SEC EDGAR public filings as of August 6, 2026.